http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
양광영,임경택,이동하,김택현,김인권 朝鮮大學校 機械技術硏究所 1999 機械技術硏究 Vol.2 No.1
The purpose of this work is to investigate fatigue damage of quasi-isotropic laminates under tensile loading in different directions. Low cycle fatigue tests of [O/-60/+60]s laminates and [+30/-30/90]s laminates were carried out. Materials systems used are AS4/Epoxy and AS4/PEEK. The fatigue damage of [+30/-30/90]s is very different from that of [O/-60/+60]s. The position of delamination generated at AS4/Epoxy and AS4/PEEK laminates were differentiated by the matrix difference that is, we suppose, the value of both G (critical energy release rate of mode-I) and G (critical energy release rate of mode-Ⅲ) difference. The experimental results are compared with the result obtained from the method of determining strain energy release rate components proposed by the authors.
윤성욱,김예리,김석,유광하,정상만 건국대학교 의과학연구소 1999 건국의과학학술지 Vol.9 No.-
Trousseau's syndrome refers to an association of thrombosis with visceral malignancy. The thrombophlebitis is usually recurrent and migratory. An episode of thrombosis may precede clinical recognition of malignancy by weeks or months and in many cases, the underlying malignancy was occult. Patients with a recurrent deep venous thrombophlebitis without a known predisposing factors for hypercoagulable state deserves a consideration for underlying malignancy. We report a patients with lung cancer who initially demonstrates the clinical features of the Trousseau's syndrome.
Kim, Ho Gak,Han, Jimin,Kim, Myung-Hwan,Cho, Kyu Hyun,Shin, Im Hee,Kim, Gwang Ha,Kim, Jae Seon,Kim, Jin Bong,Kim, Tae Nyeun,Kim, Tae Hyeon,Kim, Tae Hyo,Kim, Jae Woo,Ryu, Ji Kon,Moon, Young Soo,Moon, Jo WJG Press 2009 World journal of gastroenterology Vol.15 No.1
<P>To investigate prevalence of Clonorchis sinensis in patients with gastrointestinal symptoms, and the relation of the infection to hepatobiliary diseases in 26 hospitals in Korea.</P>
Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis
Kim Gwang Ha,Choi Myung-Gyu,Kim Jin Il,Lee Soo Teik,Chun Hoon Jai,Lee Kook Lae,Choi Suk Chei,Jang Jae-Young,Lee Yong Chan,Kim Jae Gyu,Kim Ki Bae,Shim Ki-Nam,Sohn Chong Il,Kim Sung Kook,Kim Sang Gyun,J 거트앤리버 소화기연관학회협의회 2023 Gut and Liver Vol.17 No.6
Background/Aims: Fexuprazan is a novel potassium-competitive acid blocker that could be of benefit to patients with gastric mucosal injury. The aim of this study was to assess the 2-week efficacy and safety of fexuprazan in patients with acute or chronic gastritis. Methods: In this study, 327 patients with acute or chronic gastritis who had one or more gastric erosions on endoscopy and subjective symptoms were randomized into three groups receiving fexuprazan 20 mg once a day (q.d.), fexuprazan 10 mg twice a day (b.i.d.), or placebo for 2 weeks. The posttreatment assessments were the primary endpoint (erosion improvement rate), secondary endpoints (cure rates of erosion and edema and improvement rates of redness, hemorrhage, and subjective symptoms), and drug-related adverse events. Results: Among the patients, 57.8% (59/102), 65.7% (67/102), and 40.6% (39/96) showed erosion improvement 2 weeks after receiving fexuprazan 20 mg q.d., fexuprazan 10 mg b.i.d., and placebo, respectively. Both fexuprazan 20 mg q.d. and 10 mg b.i.d. showed superior efficacy to the placebo (p=0.017 and p<0.001, respectively). Likewise, both fexuprazan 20 mg q.d. and 10 mg b.i.d. also showed higher erosion healing rates than the placebo (p=0.033 and p=0.010, respectively). No difference was noted in the edema healing rate and the improvement rates for redness, hemorrhage, and subjective symptoms between the fexuprazan and placebo groups. No significant difference was noted in the incidence of adverse drug reactions. Conclusions: Fexuprazan 20 mg q.d. and 10 mg b.i.d. for 2 weeks showed therapeutic efficacy superior to that of placebo in patients with acute or chronic gastritis
Is it possible to differentiate gastric GISTs from gastric leiomyomas by EUS?
Kim, Gwang Ha,Park, Do Youn,Kim, Suk,Kim, Dae Hwan,Kim, Dong Heon,Choi, Cheol Woong,Heo, Jeong,Song, Geun Am WJG Press 2009 WORLD JOURNAL OF GASTROENTEROLOGY Vol.15 No.27
<P>To evaluate the ultrasonography (EUS) features of gastric gastrointestinal stromal tumors (GISTs) as compared with gastric leiomyomas and then to determine the EUS features that could predict malignant GISTs.</P>
Kim, Beom Jin,Kim, Hyun-Soo,Song, Hyun Joo,Chung, Il-Kwun,Kim, Gwang Ha,Kim, Byung-Wook,Shim, Ki-Nam,Jeon, Seong Woo,Jung, Yun Jin,Yang, Chang-Hun,Kim, Ji Hyun,Kim, Tae Ho,Kim, Sang Gyun,Shin, Woon Ge The Korean Academy of Medical Sciences 2016 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.31 No.8
<P>Eradication of <I>Helicobacter pylori</I> using first-line therapy is becoming less effective. Subjects who had been treated for <I>H. pylori</I> infection were prospectively enrolled through an on-line database registry from October 2010 to December 2012. Demographic data, detection methods, treatment indication, regimens, durations, compliance, adverse events, and eradication results for <I>H. pylori</I> infection were collected. Data of 3,700 patients from 34 hospitals were analyzed. The overall eradication rate of the first-line therapy was 73.0%. Eradication failure was significantly associated with old age, concomitant medication, and comorbidity. Regional differences in eradication rates were observed. The most common first-line therapy was proton pump inhibitor-based triple therapy (standard triple therapy, STT) for 7 days (86.8%). The eradication rates varied with regimens, being 73% in STT, 81.8% in bismuth-based quadruple therapy, 100% in sequential therapy, and 90.3% in concomitant therapy. The eradication rate in treatment-naïve patients was higher than that in patients previously treated for <I>H. pylori</I> infection (73.8% vs. 58.5%, <I>P</I> < 0.001). The overall eradication rate for second-line therapy was 84.3%. There was no statistical difference in eradication rates among various regimens. <I>H. pylori</I> eradication rate using STT is decreasing in Korea and has become sub-optimal, suggesting the need for alternative regimens to improve the efficacy of first-line therapy for <I>H. pylori</I> infection.</P>
Beom Jin Kim,Hyuk Lee,Yong Chan Lee,Seong Woo Jeon,Gwang Ha Kim,Hyun-Soo Kim,Jae Kyu Sung,Dong Ho Lee,Heung Up Kim,Moo In Park,Il Ju Choi,Soon Man Yoon,Sang Wook Kim,Gwang Ho Baik,Ju Yup Lee,Jin Il Ki 거트앤리버 소화기연관학회협의회 2019 Gut and Liver Vol.13 No.5
Background/Aims: This nationwide, multicenter prospective randomized controlled trial aimed to compare the efficacy and safety of 10-day concomitant therapy (CT) and 10-day sequential therapy (ST) with 7-day clarithromycin-containing triple therapy (TT) as first-line treatment for Helicobacter pylori infection in the Korean population. Methods: Patients with H. pylori infection were assigned randomly to 7d-TT (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 7 days), 10d-ST (lansoprazole 30 mg and amoxicillin 1 g twice daily for the first 5 days, followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg twice daily for the remaining 5 days), or 10d-CT (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 10 days). The primary endpoint was eradication rate by intention-to-treat (ITT) and per-protocol (PP) analyses. Results: A total of 1,141 patients were included. The 10d-CT protocol achieved a markedly higher eradication rate than the 7d-TT protocol in both the ITT (81.2% vs 63.9%) and PP analyses (90.6% vs 71.4%). The eradication rate of the 10d-ST protocol was superior to that of the 7d-TT protocol (76.3% vs 63.9%, ITT analysis; 85.0% vs 71.4%, PP analysis). No significant differences in adherence or serious side effects were found among the three treatment arms. Conclusions: The 10d-CT and 10d-ST regimens were superior to the 7d-TT regimen as standard first-line treatment in Korea.
한국에서 지역에 따른 Helicobacter pylori 균주 내성
김재연 ( Jae Yeon Kim ),김나영 ( Na Young Kim ),김성중 ( Sung Jung Kim ),백광호 ( Gwang Ho Baik ),김광하 ( Gwang Ha Kim ),김정목 ( Jung Mogg Kim ),남령희 ( Ryoung Hee Nam ),김홍빈 ( Hong Bin Kim ),이동호 ( Dong Ho Lee ),정현채 ( H 대한소화기학회 2011 대한소화기학회지 Vol.57 No.4
Background/Aims: This study was performed to compare the prevalence rates of primary antibiotic resistance in Helicobacter pylori (H. pylori) isolates among different regions of Korea. Methods: H. pylori were isolated from gastric mucosal biopsy specimens of 99 Koreans who lived in Gyeonggi (n=40), Kangwon province (n=40) and Busan (n=19) from April to August in 2008. All the patients had no history of H. pylori eradication therapy. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin were tested according to the agar dilution method. Results: There was a difference in resistance to clarithromycin in three institutes located among Gyeonggi (32.5%), Kangwon province (12.5%) and Busan (42.1%) by One way ANOVA test (p=0.027) and nonparametric Kruskal Wallis test (p=0.027). However, by post-hoc analysis, there was no statistically significant difference among three regions. Similarly, the other 7 antibiotics (amoxicillin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin) did not show any significant difference. Conclusions: There was no significant regional difference of the primary antibiotic resistance of H. pylori. However, the included patient number might not be enough for this conclusion demanding further evaluations. (Korean J Gastroenterol 2011;57:221-229)
A Prospective Nationwide Study of Drug-Induced Liver Injury in Korea :
Suk, Ki Tae,Kim, Dong Joon,Kim, Chang Hoon,Park, Seung Ha,Yoon, Jai Hoon,Kim, Yeon Soo,Baik, Gwang Ho,Kim, Jin Bong,Kweon, Young Oh,Kim, Byung Ik,Kim, Seok Hyun,Kim, In Hee,Kim, Ju Hyun,Nam, Soon Woo American College of Gastroenterology 2012 The American journal of gastroenterology Vol.107 No.9
Kim, Dong Uk,Kang, Dae Hwan,Kim, Gwang Ha,Song, Geun Am,Kim, Chang Won,Kim, Suk,Jang, Ae Lee Lippincott Williams Wilkins, Inc. 2013 European journal of gastroenterology & hepatology Vol.25 No.1
BACKGROUND: The usefulness of bilateral stent placement for malignant hilar obstruction is still under debate. Nevertheless, many endoscopists advocate the placement of an endoscopic bilateral metal stent using various new devices and techniques. OBJECTIVES: We compared the technical and clinical efficacy, and the short-term and long-term complications of the ‘stent-in-stent’ method using a Y-stent for malignant hilar obstruction between the early and the late period of this study. MATERIALS AND METHODS: Ninety-seven patients treated with Y-stent implantation for malignant hilar obstruction were enrolled retrospectively. In 31 patients treated during the early period, bilateral Y-configured metal stents were placed for malignant hilar obstruction using the older designed Y-stent and a closed-cell second stent. The newly designed Y-stent and a slimmer open-cell second stent were introduced in 66 patients treated during the late period. New techniques learned through experience were gradually applied throughout the entire study period. RESULTS: The rate of successful placement of bilateral stents was significantly higher in patients treated during the late period than those treated during the early period (58.1 vs. 87%; P=0.001). The functional success rate was 97.3%, with no difference between the early and the late periods. Cholangitis occurred as an early complication more frequently during the early period than during the late period (16.1 vs. 1.5%; P=0.012). Cholecystitis as a late complication occurred in 21 of 76 patients (27.6%). The incidence of late complications was similar between the early and the late periods. CONCLUSION: With the development of new devices and increased technical experience, there were better outcomes during the late period compared with the early period. Endoscopic bilateral metal stenting using a Y-stent is an attractive option for the palliative treatment of malignant hilar obstruction.